Plain-English translation of NCT06995729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new migraine medication called in children ages 6 to 12. Researchers want to understand how safe the medication is, how well children tolerate it, and how the body processes it after a single dose delivered as a nasal spray. This information will help doctors know whether this treatment might be helpful for children with migraines.
Currently, there are limited treatment options available for children with migraines, especially fast-acting medicines they can use on their own. This trial is exploring whether this medication could offer a new, easier way for children to treat their migraines at home.
You likely qualify if…
You likely don't qualify if…
If you enroll, your child will receive a single dose of the medication as a nasal spray into one nostril. The dose will be based on your child's weight. Your family will visit the study clinic 3 times over about 10 weeks and receive 2 follow-up phone calls to check in on how your child is doing and to watch for any side effects.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States